Note 12 - Subsequent Event

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Subsequent Events [Text Block]

12. Subsequent Event

On

August 9, 2018,

Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm and current stockholder, agreed to invest

$20

million in BioLife to support the Company’s growth strategy of acquiring synergistic cell and gene therapy manufacturing tools and services or technologies. Casdin’s private purchase of an additional

1,428,571

newly issued shares of common stock at a price of

$14.00

per share was pursuant to a share purchase agreement, pursuant to which Casdin also agreed to restrict any re-sale of the new se shares for a

12

month period.